Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...
IPWatchdog2d
The Growing Market for Weight Loss Treatments: Innovation, Patents, and the Future of GLP-1 Agonists
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...
What Does the Future Hold for Eli Lilly?
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Mounjaro menu plan: What foods to eat and avoid for optimal results
Mounjaro can cause mild to moderate side effects, such as nausea, vomiting, constipation, and indigestion. According to Eli ...
Investors betting on the Trump trade may be missing some real risks
Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.
A drug got recalled after someone saw ‘black matter’ that can cause stroke or death
Provepharm said it pulled lot No. 24020027 with December 2025 of Phenylephrine hydrochloride Injection, USP, 10 mg/mL after ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Why Novo Nordisk surged 14% on new weight-loss drug results
Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Hosted on MSN8d
MicroAire closes deal to acquire adipose tissue biotech NEOSYAD
US-based MicroAire Surgical Instruments has acquired NEOSYAD, a developer of technology for adipose tissue engineering.
T-Net9d
Lexaria Says Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound
Lexaria Bioscience Corp., a global innovator in drug delivery platforms, has announced partial final results showcasing the ...